Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · SCHEDULE 13D

Psyence Biomedical Ltd.

PBMNASDAQEQUITYCurrent

SEC Filing

Filed Jun 3, 2026Accepted Jun 3, 2026, 9:28 AM EDTCIK 1985062Accession 0001213900-26-064484
Share

Company context

Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.

Current securities

Recent company filings

  1. 6-K filingSep 23, 2026
  2. 6-K filingSep 14, 2026
  3. EFFECT filingSep 1, 2026
  4. S-8 filingAug 26, 2026
  5. F-3 filingAug 26, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗